公开(公告)号：US20230137351A1

公开(公告)日：2023-05-04

申请号：US16349965

申请日：2017-11-14

Applicant: AMGEN INC.

Inventor： Wei YAN ,  Zhi LIU ,  Christopher MURAWSKY ,  Chadwick Terence KING ,  Yang LI ,  Zhonghua HU ,  Desiree LIM

IPC: C07K16/46

Abstract: The present invention relates to bispecific or biparatopic antigen binding proteins, polynucleotides encoding the same, and methods of making bispecific or biparatopic antigen binding proteins. Also described herein is a method to assemble IgG-like biparatopic or bispecific antibodies from VH only antigen binding proteins.

公开(公告)号：US20240103009A1

公开(公告)日：2024-03-28

申请号：US18275855

申请日：2022-02-04

Applicant: AMGEN INC.

Inventor： Karyn E. MCFADDEN ,  Brian M. CHAN ,  Christopher MURAWSKY ,  Aaron George WINTERS ,  Daniel SANTOS

IPC: G01N33/68 ,  C07K16/00 ,  C12N5/0781

CPC classification number: G01N33/6854 ,  C07K16/00 ,  C12N5/0635 ,  C07K2317/14 ,  C07K2317/92

Abstract: Provided herein are methods of monitoring for the production of select antibodies in a non-human animal, comprising (a) immunizing a non-human animal with an immunogen; (b) obtaining a blood sample comprising antibody secreting cells (ASCs) from said non-human animal; and (c) individually assaying ASCs present in the blood sample, or a fraction thereof, for the production of select antibodies. Methods of guiding antibody production in a non-human animal for the production of select antibodies are also provided. In exemplary embodiments, the method comprises performing a cycle of (a) to (c), as above, and repeating the cycle when the percentage of ASCs producing select antibodies is below a threshold. In various aspects, the cycle is repeated until the percentage of ASCs producing select antibodies is at or above a threshold. Single cell assays are further provided herein.

公开(公告)号：US20220025059A1

公开(公告)日：2022-01-27

申请号：US17332578

申请日：2021-05-27

Applicant: AMGEN INC.

Inventor： Junming YIE ,  Donghui SHI ,  David J. LLOYD ,  Jinghong WANG ,  Glenn N. SIVITS, JR. ,  Murielle M. VENIANT-ELLISON ,  Renee KOMOROWSKI ,  Neeraj AGRAWAL ,  Darren L. BATES ,  Brandon C. P. CLAVETTE ,  Ian N. FOLTZ ,  Shu-yin HO ,  Christopher MURAWSKY ,  Xiaoshan MIN ,  Zhulun WANG

IPC: C07K16/28

Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.

公开(公告)号：US20210163621A1

公开(公告)日：2021-06-03

申请号：US17046731

申请日：2019-04-10

Applicant: AMGEN INC. ,  Kite Pharma, Inc.

Inventor： Michael John Giffin ,  Melissa THOMAS ,  Christopher MURAWSKY ,  Ryan B. CASE ,  Lawren WU ,  Jed J. WILTZIUS ,  Ruben Alvarez RODRIGUEZ ,  Jun FENG

IPC: C07K16/30 ,  A61P35/00 ,  C12N15/86 ,  C07K14/705

Abstract: Antigen binding molecules, chimeric receptors, and engineered immune cells to DLL3 are disclosed in accordance with the invention. The invention further relates to vectors, compositions, and methods of treatment and/or detection using the DLL3 antigen binding molecules and engineered immune cells.

公开(公告)号：US20170275370A1

公开(公告)日：2017-09-28

申请号：US15387542

申请日：2016-12-21

Applicant: AMGEN INC.

Inventor： Junming YIE ,  Donghui SHI ,  David J. LLOYD ,  Jinghong WANG ,  Glenn N. SIVITS, JR. ,  Murielle M. VENIANT-ELLISON ,  Renee KOMOROWSKI ,  Neeraj AGRAWAL ,  Darren L. BATES ,  Brandon C. P. CLAVETTE ,  Ian N. FOLTZ ,  Shu-yin HO ,  Christopher MURAWSKY ,  Xiaoshan MIN ,  Zhulun WANG

IPC: C07K16/28 ,  A61K39/395 ,  A61K38/26 ,  A61K9/00

CPC classification number: C07K16/2869 ,  A61K9/0019 ,  A61K38/1703 ,  A61K38/26 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/54 ,  C07K2299/00 ,  C07K2317/21 ,  C07K2317/32 ,  C07K2317/33 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.